Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Data Readouts from Phase 1 AdCOVID™ and ALT-801 Clinical Trials Expected in June

Altimmune Announces First Quarter 2021 Financial Results and Provides a Corporate Update

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.

Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The results showed that a single dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.

Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose

Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2

Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline

Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?

Altimmune Inc (NASDAQ: ALT) has reported data from Phase 1b trial evaluating its NasoShield intranasal anthrax vaccine candidate. The 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.

Altimmune's Anthrax Vaccine Candidate Shows Early Safety, Immunogenicity In Healthy Volunteers

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The clinical trial was conducted with support from the Biomedical Advanced Research and Development Authority (BARDA).

Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™

Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination

Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate

If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.

Is Altimmune a Buy?

Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.

Intranasal COVID-19 Vaccine Shows Very Promising Preclinical Results

The stock price of Altimmune Inc (NASDAQ: ALT) has increased by over 10% pre-market. This is why it happened.

ALT Stock Price Increases Over 10% Pre-Market: Why It Happened

Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID. The data showed that a single intranasal dose of AdCOVID provided 100% protection against the SARS-CoV-2 virus.

Altimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies

ContraFect

Evoke Pharma

Novavax

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the stocks are moving.

Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday

The stock price of Altimmune Inc (NASDAQ: ALT) increased by over 15% pre-market. This is why it happened.

ALT Stock Price Increases Over 15% Pre-Market: Why It Happened

Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas.

Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza

Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility

Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza

Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing international independent power producer (IPP), headquartered in Ireland, with a focus on the midsized utility solar photovoltaic (PV) market, saw its full-year revenues increase by 77% year-on-year to €4.1 million in 2020, with Italy the largest revenue contributor at 41%, the Netherlands at 32%, and Romania 24% The group posted an EBITDA of €2.6 million as gross margins from operating parks almost doubled to €3.2 million, while corporate overhead costs reduced by 26%. Alternus Energy expects its EBITDA to increase to €18m in 2021 on completion of contracted acquisitions.

Alternus Energy shows turn to positive EBITDA and strong revenue growth in financial results for year ended December 31, 2020

Alternus Energy shows turn to positive EBITDA and strong revenue growth in financial results for the year ended December 31, 2020

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021. Also, Altimmune's Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.

Altimmune to Present at Upcoming Conferences

Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particularly strong in Europe.  Alternus has grown in four years from being a small Romania-based operator of two solar parks with 6 MWp to becoming a pan-European independent power producer with 25 solar photovoltaic (PV) parks and a total installed capacity of 30.5 MWp in four countries.

Alternus Energy harnesses the power of the sun to play a leading role in the green energy drive

Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript

Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine.

Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate

Nasal spray may offer room temperature distribution that could reduce logistical  challenges for healthcare systems and providers

Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate

GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.

News for Altimmune Stock (ALT)